Bradykinin initiates cytokine‐mediated inflammatory hyperalgesia

@article{Ferreira1993BradykininIC,
  title={Bradykinin initiates cytokine‐mediated inflammatory hyperalgesia},
  author={S{\'e}rgio H. Ferreira and Berenice B. Lorenzetti and Stephen Poole},
  journal={British Journal of Pharmacology},
  year={1993},
  volume={110}
}
1 The hyperalgesic activities in rats of bradykinin, carrageenin and lipopolysaccharide (LPS) were investigated in a model of mechanical hyperalgesia. 2 Bradykinin and carrageenin evoked dose‐dependent hyperalgesia with maximum responses of similar magnitude to responses to LPS (1 and 5 μg). 3 Hoe 140, an antagonist of BK2 receptors, inhibited in a dose‐dependent manner hyperalgesic responses to bradykinin, carrageenin and LPS (1 μg) but not responses to LPS (5 μg), prostaglandin E2, dopamine… 
Cytokine‐mediated inflammatory hyperalgesia limited by interleukin‐1 receptor antagonist
TLDR
IL‐1ra, released at sites of inflammation, limits inflammatory hyperalgesia and appears to be the result of antagonism by IL‐ 1ra of IL‐1β‐stimulated eicosanoid production.
Role of lipocortin‐1 in the anti‐hyperalgesic actions of dexamethasone
TLDR
It is suggested that, in inflammatory hyperalgesia, inhibition of the induction of cyclo‐oxygenase 2 (COX‐2), rather than phospholipase A2, by dexamethasone and lipocortin‐12–26 contributing, in part, to this role.
Cytokine‐mediated inflammatory hyperalgesia limited by interleukin‐4
TLDR
The data suggest that IL‐4 released by mast cells limits inflammatory hyperalgesia, and that in the later phase of the response, in addition to inhibiting the production of pro‐inflammatory cytokines, IL‐ 4 also may inhibit the release of PGs.
Cytokine‐mediated inflammatory hyperalgesia limited by interleukin‐10
TLDR
The data suggest that IL‐10 limits the inflammatory hyperalgesia evoked by carrageenin and bradykinin by two mechanisms: inhibition of cytokine production and inhibition of IL‐1β evoked PGE2 production.
A cascade of cytokines mediates mechanical inflammatory hypernociception in mice.
TLDR
Results extend to mice the concept that the release of primary mediators responsible for hypernociception is preceded by a cascade of cytokines.
Blockade of inflammatory hyperalgesia and cyclooxygenase-2
TLDR
Using specific antisera and COX inhibitors it is demonstrated that interleukin-lβ (IL-1β) is a key cytokine for the release of prostaglandins (PG) and induction of COX-2 is a limiting process in the development of inflammatory hyperalgesia.
Involvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin‐induced orofacial nociception in rats
TLDR
The response seems to be more susceptible to inhibition by B2 receptor antagonist and selective COX‐2 inhibitor than by B1 receptor antagonist or nonselective COX inhibitor, and to sympathetic amines and PGs (but not leukotrienes).
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Interleukin‐8 as a mediator of sympathetic pain
TLDR
IL‐8 is the first endogenous mediator to be identified as evoking hyperalgesia involving the sympathetic nervous system, and a new biological activity of IL-8 is described, namely the capacity to evoke hyperAlgesia by a prostaglandin‐independent mechanism.
The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesia
TLDR
Results show that TNFα has an early and crucial role in the development of inflammatory hyperaglesia and the finding that the production of these cytokines is inhibited by steroidal anti‐inflammatory drugs provides a mechanism of action for these drugs in the treatment ofinflammatory hyperalgesia.
The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia.
TLDR
The delineation of the role of TNF alpha,IL-1 beta, IL-6 and IL-8 in the development of inflammatory hyperalgesia taken together with the finding that the production of these cytokines is inhibited by steroidal anti-inflammatory drugs provides a mechanism of action for these drugs in the treatment ofinflammatory hyperalGESia.
A peripheral sympathetic component in inflammatory hyperalgesia.
Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue
TLDR
An analgesic tripeptide analogue of IL-1β is developed which antagonizes hyperalgesia evoked by IL- 1β and by the inflammatory agent carrageenan.
Bradykinin and inflammatory pain
...
...